Results 21 to 30 of about 661,753 (260)
The role of coagulation hemostasis for development of early-onset preeclampsia in low-risk patients
Акушерство, гинекология и репродукция, 2022 Aim: to determine a role of specific parameters of coagulation hemostasis for development of severe early-onset preeclampsia (еPE) in low-risk patients.Materials and Methods.
M. G. Nikolaeva +4 more
doaj +1 more source
Oman Medical Journal, 2013 Objectives: This study was aimed to determine plasma levels of total (TFPI-T) and free (TFPI-F) tissue factor pathway inhibitor, plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) in a cohort of Saudi patients with chronic
Syed Shahid Habib
doaj +1 more source
Tissue factor pathway inhibitor is an inhibitor of factor VII‐activating protease [PDF]
Journal of Thrombosis and Haemostasis, 2012 Factor VII-activating protease (FSAP) is a serine protease that circulates in plasma in its inactive single-chain form and can be activated upon contact with dead cells. When activated by apoptotic cells, FSAP leads to the release of nucleosomes. The serpins C1-inhibitor and α(2) -antiplasmin are reported to be the major inhibitors of FSAP.
Stephan, F. +7 more
openaire +2 more sources
Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis
Arthritis Research & Therapy, 2019 Objective This study evaluates the utility of urinary pro-thrombotic molecules such as tissue factor (TF), anti-thrombotic molecules such as tissue factor pathway inhibitor (TFPI), and fibrinolytic molecules such as plasmin and d-dimer as biomarkers of ...
Ling Qin +10 more
doaj +1 more source
Platelets, 2020 The aim of the study was to evaluate diurnal changes of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) concentrations in relation to on-treatment platelet reactivity.
Joanna Boinska +7 more
doaj +1 more source
Low levels of tissue factor pathway inhibitor increase the risk of cerebral venous thrombosis
Advanced Biomedical Research, 2015 Background: Decreased concentration of tissue factor pathway inhibitor (TFPI) is a risk factor for development of deep venous thrombosis and coronary heart disease, but there is no evidence for the relationship between TFPI and cerebral venous and sinus ...
Shaghayegh Haghjooy Javanmard +2 more
doaj +1 more source
Haematologica, 2010 Background Heparanase is an endo-β-D-glucuronidase dominantly involved in tumor metastasis and angiogenesis. Recently, we demonstrated that heparanase is involved in the regulation of the hemostatic system.
Yona Nadir +5 more
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng +3 more
wiley +1 more source
Tissue factor pathway inhibitor and bacterial infection [PDF]
Journal of Thrombosis and Haemostasis, 2011 See also van den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJTH, van 't Veer C, van der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. This issue, pp 122-32.
S A, Maroney, A E, Mast
openaire +2 more sources
Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity. [PDF]
PLoS ONE, 2012 Islet and hepatocyte transplantation are associated with tissue factor-dependent activation of coagulation which elicits instant blood mediated inflammatory reaction, thereby contributing to a low rate of engraftment.
Xavier Stephenne +7 more
doaj +1 more source